SeaBridge Investment Advisors LLC Takes $2.59 Million Position in Icon Plc $ICLR

SeaBridge Investment Advisors LLC acquired a new position in Icon Plc (NASDAQ:ICLR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 14,795 shares of the medical research company’s stock, valued at approximately $2,589,000.

Other hedge funds have also recently bought and sold shares of the company. D.A. Davidson & CO. acquired a new position in Icon during the 3rd quarter valued at about $3,422,000. CWA Asset Management Group LLC bought a new stake in shares of Icon during the third quarter valued at approximately $224,000. Motco boosted its position in shares of Icon by 4.4% during the third quarter. Motco now owns 3,806 shares of the medical research company’s stock worth $666,000 after buying an additional 161 shares during the period. Penobscot Investment Management Company Inc. bought a new position in Icon in the 3rd quarter worth approximately $201,000. Finally, Tectonic Advisors LLC grew its holdings in Icon by 26.9% in the 3rd quarter. Tectonic Advisors LLC now owns 1,932 shares of the medical research company’s stock worth $338,000 after buying an additional 409 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ICLR shares. Barclays lifted their target price on Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. UBS Group set a $220.00 price objective on shares of Icon in a report on Friday, October 24th. Robert W. Baird set a $220.00 target price on shares of Icon in a research report on Friday, October 24th. Finally, TD Cowen lowered their target price on shares of Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Icon has a consensus rating of “Moderate Buy” and a consensus target price of $205.31.

Icon Trading Up 2.0%

Shares of Icon stock opened at $201.48 on Wednesday. The business has a fifty day simple moving average of $175.87 and a 200-day simple moving average of $172.19. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $228.29. The firm has a market cap of $16.27 billion, a price-to-earnings ratio of 27.26, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.